Market Spotlight: Cervical Cancer
Market Spotlight: Cervical Cancer
$1,318.00
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 564,900 incident cases of cervical cancer in females worldwide, and expects that number to increase to 618,400 incident cases by 2026.
- Approved drugs for cervical cancer target vascular endothelial growth factor, topoisomerase I, programmed death-1 receptor (PD-1)/programmed death ligands (PD-L1 and PD-L2), the immune system, and reactive oxygen species/free radicals. The majority of these therapies are administered via the intravenous route.
- The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with only one drug in the NDA/BLA stage.
- Therapies in development for cervical cancer focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral, subcutaneous, intramuscular, intravesical, and intranasal formulations.
- High-impact upcoming events for drugs in the cervical cancer space comprise topline Phase III trial results for Libtayo, Imfinzi, and axalimogene filolisbac, and an expected PDUFA date for biosimilar bevacizumab (Mylan/Biocon).
- The overall likelihood of approval of a Phase I solid tumors asset is 5.8%, and the average probability a drug advances from Phase III is 43.3%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.4 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for cervical cancer have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
- The US has a substantial lead in the number of cervical cancer clinical trials globally. Spain leads the major European markets, while China has the top spot in Asia.
- Roche has the highest number of completed clinical trials for cervical cancer, with 15 trials.
- AstraZeneca leads industry sponsors with the highest overall number of clinical trials for cervical cancer.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiotherapy
9 Chemotherapy
10 Targeted therapy
10 Immunotherapy
11 EPIDEMIOLOGY
14 MARKETED DRUGS
17 PIPELINE DRUGS
24 RECENT EVENTS AND ANALYST OPINION
24 Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
25 Balstilimab for Cervical Cancer (September 18, 2020)
27 Tisotumab Vedotin for Cervical Cancer (June 29, 2020)
29 GX-188E for Cervical Cancer (April 27, 2020)
31 Multiple Drugs for Cervical Cancer (February 20, 2020)
32 HLX10 for Cervical Cancer (September 12, 2019)
33 LN-145 for Cervical Cancer (July 2, 2019)
34 Axalimogene Filolisbac for Cervical Cancer (June 27, 2019)
35 Mvasi for Cervical Cancer (June 25, 2019)
36 LN-145 for Cervical Cancer (May 31, 2019)
38 Axalimogene Filolisbac for Cervical Cancer (May 15, 2019)
39 LN-145 for Cervical Cancer (May 15, 2019)
42 KEY UPCOMING EVENTS
43 KEY REGULATORY EVENTS
43 Agenus Kicks Off Rolling BLA For Balstilimab
43 Samsung Bioepis Receives EU Bevacizumab Approval
43 Biosimilar Avastin Is Launched In India
43 Mylan Reveals FDA Goal Date For Bevacizumab
45 PROBABILITY OF SUCCESS
46 LICENSING AND ASSET ACQUISITION DEALS
46 Betta Gains China-Plus Rights To Two Agenus Oncology Drugs
47 REVENUE OPPORTUNITY
48 CLINICAL TRIAL LANDSCAPE
49 Sponsors by status
50 Sponsors by phase
51 Recent events
53 BIBLIOGRAPHY
53 Prescription information
55 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of cervical cancer, 2017–26
17 Figure 2: Overview of pipeline drugs for cervical cancer in the US
17 Figure 3: Pipeline drugs for cervical cancer, by company
18 Figure 4: Pipeline drugs for cervical cancer, by drug type
18 Figure 5: Pipeline drugs for cervical cancer, by classification
25 Figure 6: Tisotumab Vedotin for Cervical Cancer (September 21, 2020): Phase II – innovaTV 204
27 Figure 7: Balstilimab for Cervical Cancer (September 18, 2020): Phase II – RaPiDS (+/- AGEN1884, 2nd Line)
29 Figure 8: Tisotumab Vedotin for Cervical Cancer (June 29, 2020): Phase II – innovaTV 204
31 Figure 9: GX-188E for Cervical Cancer (April 27, 2020): Phase Ib/IIa – w/Pembrolizumab (Korea)
32 Figure 10: Multiple Drugs for Cervical Cancer (February 20, 2020): Phase II – RaPiDS
38 Figure 11: LN-145 for Cervical Cancer (May 31, 2019): Phase II – innovaTIL-04 (C-145-04)
41 Figure 12: LN-145 for Cervical Cancer (May 15, 2019): Phase II – innovaTIL-04 (C-145-04)
42 Figure 13: Key upcoming events in cervical cancer
45 Figure 14: Probability of success in the solid tumors pipeline
48 Figure 15: Clinical trials in cervical cancer
48 Figure 16: Top 10 drugs for clinical trials in cervical cancer
49 Figure 17: Top 10 companies for clinical trials in cervical cancer
49 Figure 18: Trial locations in cervical cancer
50 Figure 19: Cervical cancer trials status
51 Figure 20: Cervical cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of cervical cancer, 2017–26
15 Table 2: Marketed drugs for cervical cancer
19 Table 3: Pipeline drugs for cervical cancer in the US
24 Table 4: Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
26 Table 5: Balstilimab for Cervical Cancer (September 18, 2020)
28 Table 6: Tisotumab Vedotin for Cervical Cancer (June 29, 2020)
30 Table 7: GX-188E for Cervical Cancer (April 27, 2020)
32 Table 8: Multiple Drugs for Cervical Cancer (February 20, 2020)
33 Table 9: HLX10 for Cervical Cancer (September 12, 2019)
34 Table 10: LN-145 for Cervical Cancer (July 2, 2019)
35 Table 11: Axalimogene Filolisbac for Cervical Cancer (June 27, 2019)
36 Table 12: Mvasi for Cervical Cancer (June 25, 2019)
37 Table 13: LN-145 for Cervical Cancer (May 31, 2019)
39 Table 14: Axalimogene Filolisbac for Cervical Cancer (May 15, 2019)
40 Table 15: LN-145 for Cervical Cancer (May 15, 2019)
47 Table 16: Historical global sales, by drug ($m), 2015–19
47 Table 17: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Renal Disease 
Sign up to the